Global Cervical Cancer Diagnostic Testing Market 2016-2020

  • ID: 3987855
  • Report
  • Region: Global
  • 111 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Abbott Molecular
  • BioVantra
  • DAAN Gene
  • Genera Biosystems
  • IncellDx
  • Qiagen
  • MORE
About Cervical Cancer Diagnostic Testing

The global cervical cancer diagnostic testing market is growing steadily, primarily due to the availability and awareness of the programs in the developed countries. This test enables women aged 21 years and above to get screened, making most of the pre-cancerous lesions identifiable at stages when they can be treated easily. In the US, National Breast and Cervical Cancer Early Detection Program (NBCCEDP) provides low-cost even free cervical cancer screening for uninsured and low-income women. As per the Affordable Care Act, all health insurance plans initiated after September 23, 2010, should provide recommended cervical cancer screening tests to end-users. In developing countries, with the widespread awareness programs by public organizations like the WHO along with government initiatives, visual inspection with acetic acid (VIA) and Lugol's iodine (VILI) are being performed to screen women. This initiative is expected to raise the market demand for cervical cancer screening and diagnostic tests.

The analysts forecast the global cervical cancer diagnostic testing market to grow at a CAGR of 6.90% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global cervical cancer diagnostic testing market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of cervical cancer testing products used to perform cervical cancer screening.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Cervical Cancer Diagnostic Testing Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Abbott Molecular
- Becton
- Dickinson & Company
- Hologic
- Qiagen
- Quest Diagnostics
- Roche Molecular Diagnostics

Other prominent vendors
- Arbor Vita
- Autogenomics
- bioMérieux
- BioVantra
- Cancer Genetics
- Cepheid
- Cervia Diagnostics
- Cytoimmun
- DAAN Gene
- Delphi Bioscience
- DiaCarta
- Fujirebio
- Genera Biosystems
- Greiner Bio-One
- Guided Therapeutics
- GynaeHealth
- IncellDx
- Micromedic Technologies
- Norchip
- OncoHealth
- OralDNA Labs
- Seegene
- Solopap International
- Trovagene

Market drivers
- Increasing global activities by public organizations.
- For a full, detailed list, view the full report

Market challenges
- Rising awareness toward cervical cancer over-screening.
- For a full, detailed list, view the full report

Market trends
- Development of new diagnostic platforms.
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Molecular
  • BioVantra
  • DAAN Gene
  • Genera Biosystems
  • IncellDx
  • Qiagen
  • MORE
Part 01: Executive summary
Highlights

Part 02: Scope of the report
Market overview
Top-vendor offerings

Part 03: Market research methodology
Research methodology
Economic indicators

Part 04: Introduction
Key market highlights
Cervical cancer: An overview

Part 05: Market landscape
Market overview
Market size and forecast
Five forces analysis

Part 06: Market segmentation by test type
Pap smear test
HPV testing
Global cervical cancer Pap smear test market
Global cervical cancer HPV testing market

Part 07: Market segmentation by technology
ELISA
FISH
NASBA
PCR
Multichromatic staining and microscopy

Part 08: Market segmentation by method
Cytopathological method
Molecular method

Part 09: Market segmentation by end-user
Hospitals
Clinical diagnostic laboratories
Homecare
Others

Part 10: Geographical segmentation
Cervical cancer diagnostic testing market in Americas
Cervical cancer diagnostic testing market in EMEA
Cervical cancer diagnostic testing market in APAC

Part 11: Buying criteria

Part 12: Market drivers
Rising prevalence of cervical cancer risk factors
Growing adoption of HPV testing
Reimbursement policies
Increasing global activities by public organizations

Part 13: Impact of drivers

Part 14: Market challenges
Rising awareness toward cervical cancer over-screening
Less public awareness and presence of social barriers
Limited number of health clinics in developing countries
Availability of visual inspection methods

Part 15: Impact of drivers and challenges

Part 16: Market trends
Development of new diagnostic platforms
Expansion into emerging markets
Emergence of novel biomarkers
Rise in use of HPV home-testing kits

Part 17: Vendor landscape
Competitive scenario
Geographical presence of key vendors
Key news

Part 18: Key vendor analysis
Abbott Molecular
Becton, Dickinson & Company (BD)
Hologic
QIAGEN
Quest Diagnostics
Roche Molecular Diagnostics
Other prominent vendors

Part 19: Appendix
List of abbreviations

Part 20: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Global cervical cancer diagnostic testing market: Analysis
Exhibit 03: Global incidence of cervical cancer 2012-2020 (thousands)
Exhibit 04: Incidences of cervical cancer in developing and developed countries 2012-2020 (in thousands)
Exhibit 05: Market overview: Global cervical cancer diagnostic testing market
Exhibit 06: Global cervical cancer diagnostic testing market ($ billions)
Exhibit 07: Global cervical cancer diagnostic testing market analysis: Developed and emerging markets
Exhibit 08: Opportunity analysis: Global cervical cancer diagnostic testing market
Exhibit 09: Five forces analysis
Exhibit 10: Global cervical cancer diagnostic testing market by test type 2015
Exhibit 11: Global cervical cancer diagnostic testing market by test type 2020
Exhibit 12: Major cervical cancer diagnostic products
Exhibit 13: Global cervical cancer Pap smear test market 2015-2020 ($ billions)
Exhibit 14: Global cervical cancer HPV testing market 2015-2020 ($ millions)
Exhibit 15: Segmentation of global cervical cancer HPV testing market by product type
Exhibit 16: Global cervical cancer diagnostic testing market segmentation by test type 2015-2020 ($ millions)
Exhibit 17: Global cervical cancer diagnostic testing market segmentation by test type 2015-2020 (%)
Exhibit 18: List of some studies for cervical cancer screening using ELISA technique
Exhibit 19: List of some studies for cervical cancer screening using FISH technique
Exhibit 20: List of some studies for cervical cancer screening using NASBA technique
Exhibit 21: List of some studies for cervical cancer screening using PCR technique
Exhibit 22: List of some studies for cervical cancer screening using Multichromatic staining and microscopy technique
Exhibit 23: Some cervical cancer diagnostic test products by technology
Exhibit 24: Global cervical cancer diagnostic testing market by method 2015
Exhibit 25: Global cervical cancer diagnostic testing market by method 2020
Exhibit 26: Global cervical cancer diagnostic testing market segmentation by end users 2015
Exhibit 27: Global cervical cancer diagnostic testing market segmentation by geography 2015
Exhibit 28: Global cervical cancer diagnostic testing market segmentation by geography 2020
Exhibit 29: Region-wise market impact: Global cervical cancer diagnostics market
Exhibit 30: Country-wise revenue and growth analysis
Exhibit 31: Global cervical cancer diagnostic testing market: Geography lifecycle analysis 2015
Exhibit 32: Market overview: Americas
Exhibit 33: Cervical cancer diagnostic testing market in Americas 2016-2020 ($ millions)
Exhibit 34: Market overview: EMEA
Exhibit 35: Cervical cancer diagnostic testing in EMEA 2016-2020 ($ millions)
Exhibit 36: Market overview: APAC
Exhibit 37: Cervical cancer diagnostic testing market in APAC 2016-2020 ($ millions)
Exhibit 38: Comparison of cervical cancer incidences in developed and developing countries 2012-2020 (in thousands)
Exhibit 39: Global cervical cancer diagnostic testing market segmentation by geography 2015-2020 (%)
Exhibit 40: Global cervical cancer diagnostic testing market segmentation by geography 2015-2020 ($ millions)
Exhibit 41: Geographical overview: Global cervical cancer diagnostic testing market
Exhibit 42: Key buying criteria for cervical cancer diagnostic testing
Exhibit 43: Buying criteria for cervical cancer diagnostic testing
Exhibit 44: Country-wise percentage of women who smoke on a daily-basis
Exhibit 45: Country-wise statistics of cervical cancer cases per 100,000 women per year
Exhibit 46: Reimbursement policies in different countries
Exhibit 47: Activities of CDC in collaboration with other public organizations for cervical cancer screening
Exhibit 48: Impact of drivers
Exhibit 49: Cervical cancer cases comparison in North-Americas and Africa
Exhibit 50: Impact of drivers and challenges
Exhibit 51: Expansion of global market leaders in developing countries/regions
Exhibit 52: List of cervical cancer diagnostic studies for novel biomarker detection
Exhibit 53: Trends and their impact
Exhibit 54: Competitive structure analysis of global cervical cancer testing market 2015
Exhibit 55: Market penetration of various cervical cancer diagnostic testing manufacturers globally (2015)
Exhibit 56: Competitive landscape analysis of global cervical cancer diagnostic testing market 2015
Exhibit 57: Strategic success factors of companies in global cervical cancer diagnostic testing market 2015
Exhibit 58: Leading vendors ranking 2015
Exhibit 59: Share of vendors in global cervical cancer diagnostic testing market 2015
Exhibit 60: Regional analysis of key vendors
Exhibit 61: Key highlights of Abbott Molecular
Exhibit 62: Abbott Molecular strength assessment
Exhibit 63: Abbott Molecular strategy assessment
Exhibit 64: Abbott Molecular opportunity assessment
Exhibit 65: Key highlights of BD
Exhibit 66: BD strength assessment
Exhibit 67: BD strategy assessment
Exhibit 68: BD opportunity assessment
Exhibit 69: Key highlights of Hologic
Exhibit 70: Hologic strength assessment
Exhibit 71: Hologic strategy assessment
Exhibit 72: Hologic opportunity assessment
Exhibit 73: Key highlights of QIAGEN
Exhibit 74: QIAGEN strength assessment
Exhibit 75: QIAGEN strategy assessment
Exhibit 76: QIAGEN opportunity assessment
Exhibit 77: Key highlights of Quest Diagnostics
Exhibit 78: Quest Diagnostics strength assessment
Exhibit 79: Quest Diagnostics strategy assessment
Exhibit 80: Quest Diagnostics opportunity assessment
Exhibit 81: Key highlights of Roche Molecular Diagnostics
Exhibit 82: Roche Molecular Diagnostics strength assessment
Exhibit 83: Roche Molecular Diagnostics strategy assessment
Exhibit 84: Roche Molecular Diagnostics opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbott Molecular
  • BioVantra
  • DAAN Gene
  • Genera Biosystems
  • IncellDx
  • Qiagen
  • MORE
New Report Released: – Global Cervical Cancer Diagnostic Testing Market 2016-2020

The author of the report recognizes the following companies as the key players in the global cervical cancer diagnostic testing market: Abbott Molecular, Becton, Dickinson & Company, Hologic, Qiagen, Quest Diagnostics, and Roche Molecular Diagnostics.

Other Prominent Vendors in the market are: Arbor Vita, Autogenomics, bioMérieux, BioVantra, Cancer Genetics, Cepheid, Cervia Diagnostics, Cytoimmun, DAAN Gene, Delphi Bioscience, DiaCarta, Fujirebio, Genera Biosystems, Greiner Bio-One, Guided Therapeutics, GynaeHealth, IncellDx, Micromedic Technologies, Norchip, OncoHealth, OralDNA Labs, Seegene, Solopap International, and Trovagene.

Commenting on the report, an analyst from the research team said: “One trend in market is expansion into emerging markets. The global vendors are inclined upon penetrating the niche market of developing countries to maximize their revenue. In India, QIAGEN has careHPV test for serving women in low-resource areas, whereas digene HC2 HPV test serves women in areas having modern healthcare infrastructure. In 2009, the company entered into a partnership with Chittaranjan National Cancer Institute, in Kolkata, to establish a large-scale cervical cancer screening program. QIAGEN's QIAGENcares, partners with PATH and Bill & Melinda Gates Foundation to improve the cervical cancer state worldwide. Not only that, QIAGEN collaborated with HPV vaccine developer Merck, to provide nearly five million free HPV vaccine doses and expanded the already existing HPV test donation program by 500,000 for screening a total of 1.5 million women in the emerging countries.”

According to the report, one driver in the market is reimbursement policies. Most of the developed countries have specific agencies that have reimbursement policies to motivate and support women to undergo diagnostic tests. Agencies such as Wittenberg Weiner Consulting (WWC) and Wisconsin Well Women Program (WWWP) in the US reimburse an office visit for a pelvic exam, Pap smear test, HPV test, colposcopy, or other invasive diagnostic procedures, case management, and administrative fees. Similarly, diagnostic clinics have also started including cervical cancer diagnostics tests in their reimbursement policies. For Instance, Roche's cobas HPV Test is covered by Selah Genomics in its own certified laboratory. These favorable reimbursements coupled with the government initiatives will drive the cervical cancer diagnostic testing market during the forecast period.

Further, the report states that one challenge in the market is rising awareness toward cervical cancer over-screening. The medical authorities worldwide suggest that HPV test should replace current Pap smear test as the primary cervical cancer screening. Till now, most of the governments in the developed countries recommended women, to undergo Pap smear test once in every two years. With the adoption of the HPV testing, which suggests women undergo the test once in every five years, not only the over-screening will be reduced, but also the governments can save on overall healthcare budgets. Based on Roche’s Athena clinical trial, the FDA acknowledged their cobas HPV test and recommended HPV testing as a replacement to Pap smear test.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Abbott Molecular
  • Becton
  • Dickinson & Company
  • Hologic
  • Qiagen
  • Quest Diagnostics
  • Roche Molecular Diagnostics
  • Arbor Vita
  • Autogenomics
  • bioMérieux
  • BioVantra
  • Cancer Genetics
  • Cepheid
  • Cervia Diagnostics
  • Cytoimmun
  • DAAN Gene
  • Delphi Bioscience
  • DiaCarta
  • Fujirebio
  • Genera Biosystems
  • Greiner Bio-One
  • Guided Therapeutics
  • GynaeHealth
  • IncellDx
  • Micromedic Technologies
  • Norchip
  • OncoHealth
  • OralDNA Labs
  • Seegene
  • Solopap International
  • Trovagene
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll